Treatment-Emergent Antibodies to Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in the ReCePI Phase III Clinical Trial

被引：0
|
作者：
Panigrahi, A. [1 ]
Pearl, R. [1 ]
Pelletier, J. [2 ]
Sodha, N. [3 ]
Reece, T. [4 ]
Nuttall, G. [5 ]
Karim, C. [6 ]
Erickson, A. [6 ]
Mufti, N. [6 ]
Benjamin, R. [6 ]
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Univ Florida, Gainesville, FL USA
[3] Rhode Isl Hosp, Providence, RI USA
[4] Univ Colorado Hosp, Denver, CO USA
[5] Mayo Clin, Rochester, MN USA
[6] Cerus Corp, Concord, CA USA
来源：
TRANSFUSION | 2024年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OA4-AM24-M
引用
收藏
页码：51A / 52A
页数：2
相关论文
共 40 条
  • [31] A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases
    Jansen, Y.
    Corthals, J.
    Wilgenhof, S.
    Schreuer, M.
    Heirman, C.
    Thielemans, K.
    Neyns, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S673 - S673
  • [32] Randomized phase III study of high-dose sequential chemotherapy (CT) supported by peripheral blood progenitor cells (PBPC) for the treatment of small cell lung cancer (SCLC): Results of the EBMT Random-ICE trial.
    Leyvraz, S.
    Pampallona, S.
    Martinelli, G.
    Ploner, F.
    Aversa, S.
    Rosti, G.
    Brunsvig, P.
    Montes, A.
    Yilmaz, U.
    Perey, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 380S - 380S
  • [33] Autologe expandierte Stammzellen aus Fettgewebe zur Behandlung komplexer kryptoglandulärer AnalfistelnEine randomisierte klinische Phase-III-Studie mit LangzeitevaluierungAutologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulasA phase III randomized clinical trial (FATT 1: Fistula Advanced Therapy Trial 1) and long-term evaluation
    J. Jongen
    coloproctology, 2013, 35 (6) : 396 - 397
  • [34] Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS"
    Grimm, Marc-Oliver
    van der Heijden, Antoine G.
    Colombel, Marc
    Muilwijk, Tim
    Martinez-Pineiro, Luis
    Babjuk, Marko M.
    Turkeri, Levent N.
    Palou, Joan
    Patel, Anup
    Bjartell, Anders S.
    Caris, Christien
    Schipper, Raymond G.
    Witjes, Wim P. J.
    Horstmann, Joerg
    Machtens, Stefan
    Mumperow, Eberhard
    Al Ghazal, Andreas
    Pulte, Thomas
    Stephan-Odenthal, Michael
    Gakis, Georgios
    Kramer, Mario
    Zaak, Dirk
    Schmitz-Draeger, Bernd
    Schreier, Holger
    Lehmann, Jan
    Werner, Torsten
    Klier, Joerg
    Marin, Jan
    Rulf, Wolfgang
    Hellmis, Eva
    Schneider, Andreas
    Spiegelhalder
    Wirth, Manfred
    Klotz, Theodor
    Suttmann, Henrik
    Siebels, Michael
    Rodemer, Gerd
    Rudolph, Robert
    Zillmann, Roger
    de Bruin, M.
    Bos, S.
    van Moorselaar, R.
    de Reijke, T.
    Boormans, J.
    Wijsman, B.
    van Melick, H. H. E.
    van Boven, E.
    Meijer, R. P.
    van der Heijden, A. G.
    Vergunst, H.
    EUROPEAN UROLOGY, 2020, 78 (05) : 690 - 698
  • [35] A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
    Yanina Jansen
    Vibeke Kruse
    Jurgen Corthals
    Kelly Schats
    Pieter-Jan van Dam
    Teofila Seremet
    Carlo Heirman
    Lieve Brochez
    Mark Kockx
    Kris Thielemans
    Bart Neyns
    Cancer Immunology, Immunotherapy, 2020, 69 : 2589 - 2598
  • [36] A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
    Jansen, Yanina
    Kruse, Vibeke
    Corthals, Jurgen
    Schats, Kelly
    van Dam, Pieter-Jan
    Seremet, Teofila
    Heirman, Carlo
    Brochez, Lieve
    Kockx, Mark
    Thielemans, Kris
    Neyns, Bart
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) : 2589 - 2598
  • [37] Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial
    Anasetti, Claudio
    Logan, Brent R.
    Lee, Stephanie J.
    Waller, Edmund K.
    Weisdorf, Daniel J.
    Wingard, John R.
    Cutler, Corey S.
    Westervelt, Peter
    Woolfrey, Ann
    Couban, Stephen
    Johnston, Laura
    Maziarz, Richard T.
    Pulsipher, Michael
    Anderlini, Paolo
    Bensinger, William I.
    Leitman, Susan F.
    Rowley, Scott D.
    Carter, Shelly L.
    Horowitz, Mary M.
    Confer, Dennis L.
    BLOOD, 2011, 118 (21) : 3 - 3
  • [38] Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702-StaMINA Trial)
    Stadtmauer, Edward A.
    Pasquini, Marcelo C.
    Blackwell, Beth
    Knust, Kristin
    Bashey, Asad
    Devine, Steven M.
    Efebera, Yvonne A.
    Ganguly, Siddhartha
    Gasparetto, Cristina
    Geller, Nancy
    Giralt, Sergio A.
    Hari, Parameswaran
    Horowitz, Mary M.
    Koreth, John
    Landau, Heather
    McCarthy, Philip L.
    McClune, Brian
    Nelson, Courtney
    Qazilbash, Muzaffar H.
    Shah, Nina
    Vesole, David H.
    Vij, Ravi
    Vogl, Dan T.
    Somlo, George
    Krishnan, Amrita
    BLOOD, 2016, 128 (22)
  • [39] GRASPA-AML 2012-01 study (NCT01810705): A multicenter, open, randomized phase 2b trial evaluating ERY001 (L-asparaginase encapsulated in red blood cells) plus low-dose cytarabine vs low-dose cytarabine alone, in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients, unfit for intensive chemotherapy.
    Thomas, Xavier G.
    Tardy, Emmanuelle Tavernier
    Guieze, Romain
    Chevallier, Patrice
    Marolleau, Jean Pierre
    Orsini, Frederique
    Hitchcock, Ian
    El-Hariry, Iman
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Reply to Emre Karabay and Ilker Tinay's Letter to the Editor re: Treatment of High-grade Non-muscle-inva- sive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066
    Grimm, Marc-Oliver
    Caris, Christien
    Witjes, Wim P. J.
    EUROPEAN UROLOGY, 2020, 78 (04) : E163 - E164
1234